SCHEMBL498265

SCHEMBL498265

CCOC(=O)C(=Cc1ccc(OC)c(OC)c1)C(=O)OCC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.69
PKM P14618 2/20 0.69
HTT P42858 1/20 0.69
MEN1 O00255 6/20 0.67
KMT2A Q03164 6/20 0.67
POLB P06746 2/20 0.67
GAA P10253 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
MAPT P10636 8/20 0.64
LMNA P02545 5/20 0.64
NPSR1 Q6W5P4 4/20 0.59
CYP1A2 P05177 3/20 0.59
CYP2C19 P33261 2/20 0.59
CYP2C9 P11712 1/20 0.59
S1PR4 O95977 1/20 0.59
S1PR1 P21453 1/20 0.59
MAPK1 P28482 1/20 0.59
PLIN1 O60240 1/20 0.58
PLIN5 Q00G26 1/20 0.58
ABHD5 Q8WTS1 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10375546 0.93 GAA (0.73) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL10375547 0.93 GAA (0.73) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL11825001 0.93 ALDH1A1 (0.64) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL11824995 0.93 ALDH1A1 (0.64) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL11459016 0.90 ALDH1A1 (0.58) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL934307 0.88 MAPT (0.70) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL29799957 0.88 MAPT (0.70) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL11466494 0.88 SMN1; SMN2 (0.57) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL11802256 0.88 MAPT (0.56) ALDH1A1PKMHTTMEN1KMT2A
SCHEMBL8330027 0.88 MAPT (0.62) ALDH1A1PKMHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells NORTHEAST NORMAL UNIVERSITY (CN) 2020-07-28 US claimed
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS NORTHEAST NORMAL UNIVERSITY (CN) 2018-07-12 US claimed
CN-104726399-A Application of ethyl p-methoxycinnamate and derivatives thereof to maintaining self-renewal and pluripotency of stem cells UNIV NORTHEAST NORMAL 2015-06-24 CN claimed
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells NORTHEAST NORMAL UNIVERSITY (CN) 2020-07-28 US disclosed
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS NORTHEAST NORMAL UNIVERSITY (CN) 2018-07-12 US disclosed
CN-104726399-A Application of ethyl p-methoxycinnamate and derivatives thereof to maintaining self-renewal and pluripotency of stem cells UNIV NORTHEAST NORMAL 2015-06-24 CN disclosed
EP-2157084-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA CO (JP) 2013-05-22 EP disclosed
US-8106053-B2 5-phenyl-3-pyridazinone derivative KOWA COMPANY, LTD. 2012-01-31 US disclosed
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA COMPANY, LTD. (JP) 2010-08-05 US disclosed
EP-2157084-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE Kowa Company, Ltd. (JP) 2010-02-24 EP disclosed
EP-0933366-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME NIKKEN CHEMICALS CO LTD (JP) 2005-04-06 EP disclosed
US-6235739-B1 ANTIINFLAMMATORY AGENTS; ANTIHISTAMINES; SKIN DISORDERS NIKKEN CHEMICALS CO., LTD. (JP) 2001-05-22 US disclosed
EP-0933366-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME Nikken Chemicals Company, Limited (JP) 1999-08-04 EP disclosed
US-5705545-A HINDERED AMINE LIGHT STABILIZER COMPOUND FOR THERMOPLASTIC POLYMERS CLARIANT FINANCE (BVI) LIMITED (VG) 1998-01-06 US disclosed
US-5414108-A From a Meldrum's acid derivative BIOGAL GYOGYSZERGRAR (HU) 1995-05-09 US disclosed
US-5350872-A Decyclization and decarboxylation of a 1,3-dioxane-4,6-dione BIOGAL GYOGYSZERGRAR (HU) 1994-09-27 US disclosed
EP-0578850-A1 Process for the preparation of carboxylic acids and derivatives of them BIOGAL GYOGYSZERGYAR (HU) 1994-01-19 EP disclosed
EP-0381235-B1 PYRROLIDINE COMPOUND AND PHARMACEUTICAL USE Eisai Co., Ltd. (JP) 1993-07-28 EP disclosed
EP-0381235-A2 Pyrrolidine compound and pharmaceutical use Eisai Co., Ltd. (JP) 1990-08-08 EP disclosed
US-4284621-A SUNSCREEN FOR SKIN BAYER AKTIENGESELLSCHAFT (DE) 1981-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS XPA, MEP1A, EED ALDH1A1 107/4885PKM 2068/4885HTT 3784/4885
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells XPA, MEP1A, EED ALDH1A1 107/4885PKM 2068/4885HTT 3784/4885
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE SERPINE1, MMP1, PLAT ALDH1A1 818/4885PKM 654/4885HTT 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.